ANI expands leadership team with 3 executive appointments
ANI is welcoming three key pharmaceutical executives: Christopher Mutz as chief commercial officer and head of rare diseases, Ori Gutwerg as senior vice president of generics and Davinder Singh as general manager of Canadian operations.
“We are delighted to welcome Chris, Ori and Davinder to ANI,” said Nikhil Lalwani, president and CEO. “Their collective experience and individual areas of expertise strengthen our team to accelerate future growth across our business units.”
Lalwani added, “Chris will build and lead the Cortrophin commercial franchise, including our launch strategy and commercial plan. Ori and Davinder will bolster our Generics and CDMO businesses. Since taking on the CEO role at ANI, I have taken the time to understand our capabilities and have identified ways in which to leverage our industry-leading infrastructure to maximize current and future market opportunities. Enhancing our leadership team reinforces our strong foundation to capture these opportunities and achieve the full potential of our business.”
Chris Mutz brings deep experience in the successful commercialization of rare disease therapies, spending more than eight years with Alexion Pharmaceuticals. Most recently, as vice president of the U.S. Neurology Business unit, he was responsible for building and leading the successful launch of Soliris (eculizumab) for gMG and NMOSD in the United States. At Alexion, he also served as vice president of the U.S. Metabolic Business Unit and national sales director of the U.S. Metabolic Business unit. Prior to joining Alexion in 2011, Mutz served in commercial roles of increasing responsibility over the course of 11 years at Merck.
Ori Gutwerg is a seasoned leader and brings more than 17 years of experience building and driving growth in pharmaceutical companies. Most recently, Gutwerg served as vice president and head of U.S. generics Rx at Taro Pharmaceuticals, overseeing a portfolio of nearly 300 generic and branded products. In that role, he drove double-digit top- and bottom-line growth, improved working capital through cost savings and efficiencies, rationalized the R&D pipeline and negotiated numerous business development deals to accelerate growth. Prior to joining Taro, he held positions with Xiromed US, Perrigo Pharmaceuticals, and Agis Group.
Davinder Singh joined ANI in December 2020. He brings more than 30 years of experience managing multiple sites within the pharmaceuticals, nutraceuticals, cosmetics and food industries. He has significant expertise across various dosage forms, including solids, semi-solids, liquids and APIs. Singh has held management positions at several multinational pharmaceutical companies, most recently at Eurofins CDMO Alphora, where he was responsible for five sites.
Prior to that, Singh held positions at Valeant Pharmaceuticals, Apotex, and Fisher Scientific/Patheon. His experience and expertise include business expansion strategy, integration, acquisitions, change management, new drug submissions, building and expanding plants and laboratories, consolidations, manufacturing, logistics, engineering, quality, safety, and information technology security.
ANI also announced that Robert Schrepfer, senior vice president of business development and specialty sales will be leaving ANI next month to pursue a new opportunity. “Rob has played a critical leadership role in ANI’s journey over the years including, but not limited to prolific deal-making. We appreciate very much Rob’s unstinted efforts for ANI over 15 years and wish him the very best in his future endeavors,” Lalwani said.